There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .
Vitamin D serum levels are associated with handgrip strength but not with muscle mass or length of hospital stay after hip fracture.
OBJECTIVES The aim of this study was to evaluate the association between serum levels of 25(OH ) vitamin D3  with midupper arm muscle circumference ( MUAMC ) , h and grip strength and length of hospital stay ( LOS ) after hip fracture . METHODS In total , 102 consecutive patients with hip fracture over the age of 65 were admitted to the orthopedic unit and prospect ively evaluated . All of the patients were treated according to specific protocol s depending on the type of fracture .  Anthropometric measurements and h and grip strength were performed , and blood sample s were taken for serum biochemistry and 25(OH ) vitamin D3 analysis within the first 72 h of admission . All of the patients were followed during their hospital stay , and the length of stay was recorded . RESULTS Of the patients , two were excluded because of pathologic fractures . In total , 100 patients with a mean age of 80 ± 7 y were included in the analysis . Among these patients , 73 % were female , and 37 % had vitamin D deficiency . The median LOS was 7 ( 5 - 11 ) d. Patients with vitamin D deficiency had lower h and grip strength in univariate analysis . In the multiple linear regression analysis with robust st and ard error , serum vitamin D levels adjusted by age and sex were associated with h and grip strength but not with MUAMC and LOS after hip fracture . CONCLUSIONS In conclusion , vitamin D serum levels were associated with h and grip strength but not with muscle mass or length of hospital stay after hip fracture
There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .